Memory advancement by intranasal insulin in type 2 diabetes (MemAID) randomized controlled clinical trial: Design, methods and rationale

Type 2 diabetes mellitus (T2DM) accelerates brain aging and increases the risk for dementia. Insulin is a key neurotrophic factor in the brain, where it modulates energy metabolism, neurovascular coupling, and regeneration. Impaired insulin-mediated brain signaling and central insulin resistance may contribute to cognitive and functional decline in T2DM. Intranasal insulin (INI) has emerged as a potential therapy for treating T2DM-related cognitive impairment.

Source: Contemporary Clinical Trials - January 6, 2020 Category: Radiology Authors: B. Galindo-Mendez, J.A. Trevino, R. McGlinchey, C. Fortier, V. Lioutas, P. Novak, C. Mantzoros, L. Ngo, V. Novak Source Type: research